PepGen Inc. (PEPG) Stock Score, Valuation & Financial Research

PepGen Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PEPG

PepGen Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.50. These figures are a research snapshot, not a buy or sell recommendation.

What PepGen Inc. does

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

PepGen is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future strategic collaborations to fund the research, development, and clinical testing of its proprietary Enhanced Delivery Oligonucleotide (EDO) platform and product candidates.

Products and services

  • The company is developing a pipeline of oligonucleotide therapeutics for neuromuscular and neurological diseases, including PGN-EDO51, PGN-EDODM1, PGN-EDO53, PGN-EDO45, and PGN-EDO44.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of its drug candidates for preclinical and clinical studies. Source

Business strengths to evaluate

  • Proprietary Enhanced Delivery Oligonucleotide (EDO) platform technology Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PEPG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.50
Market capitalization:
172.58M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -71.94M
Free cash flow:
USD -81.9M
Cash:
USD 22.76M
Total debt:
USD 16.09M
EPS:
USD -1.50

What stands out

  • Free cash flow is USD -81.9M, negative for the stored period.
  • The balance sheet shows USD 22.76M of cash versus USD 16.09M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PEPG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PEPG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PEPG's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PEPG to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PEPG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PEPG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.